1. Home
  2. AGIO vs CLM Comparison

AGIO vs CLM Comparison

Compare AGIO & CLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

HOLD

Current Price

$30.34

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Logo Cornerstone Strategic Value Fund Inc. New

CLM

Cornerstone Strategic Value Fund Inc. New

HOLD

Current Price

$7.42

Market Cap

2.2B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
AGIO
CLM
Founded
2007
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance/Investors Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
2.2B
IPO Year
2013
1995

Fundamental Metrics

Financial Performance
Metric
AGIO
CLM
Price
$30.34
$7.42
Analyst Decision
Buy
Analyst Count
8
0
Target Price
$38.88
N/A
AVG Volume (30 Days)
1.1M
1.5M
Earning Date
04-29-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$43,011,000.00
N/A
Revenue This Year
$76.75
N/A
Revenue Next Year
$170.73
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$22.24
$6.92
52 Week High
$46.00
$8.53

Technical Indicators

Market Signals
Indicator
AGIO
CLM
Relative Strength Index (RSI) 33.83 48.63
Support Level $26.71 $7.33
Resistance Level $36.07 $7.70
Average True Range (ATR) 1.89 0.10
MACD -1.07 -0.01
Stochastic Oscillator 24.50 54.55

Price Performance

Historical Comparison
AGIO
CLM

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.

About CLM Cornerstone Strategic Value Fund Inc. New

Cornerstone Strategic Value Fund Inc is a closed-end management investment company. The fund's objective is to seek long-term capital appreciation through investments in equity securities of U.S. and non-U.S. companies. It invests in various sectors, which include financials, information technology, healthcare, consumer discretionary, Consumer Staples, utilities, energy, Real Estate, materials, and other sectors.

Share on Social Networks: